CAD and breast carcinoma: Palbociclib49, an FDA-approved CDK4/6 inhibitor for breast cancer, blocked S1900 phosphorylation of CAD in KSHV de novo infected HOKs (Fig. 7A) and KSHV-positive BCBL-1 lymphoma cells (Fig. 7B).